Poxel announces positive top line data for a PK/PD clinical study of the new oral anti-sugar drug imeglimin

recently, france's Poxelcompany(http://and partner me
tavant Sciences jointly announced the positive top line data for a PK/PD clinical study of the new oral sugar-reducing drug imegliminThe study assessed the safety, tolerance, pharmacokinetics (PK) and pharmacokinetics (PD) of imeglimin in patients with type 2 diabetes (T2D) and stage 3b/4 chronic kidney disease (CKD)The results showed that the study reached its main endpoint, with imeglimin having good tolerance and safety in this particular patient population, and PK and PD data were consistent with previous data from PoxelThese data demonstrate the therapeutic potential of imeglimin in this groupBased on these data, me
tavant has planned to launch a Phase III clinical project in the United States and the European Union to evaluate imeglimin for use in patients with T2D and stage 3b/4 CKDAbout imeglimin
imeglimin belongs to a new class of oral chemicals called Glimins, is the first candidateproduct
(http://to enter clinical development in thisdrug(http://, with a unique mechanism of action, targeting mitocho bioenergy (mitocho
ndrialalcs, a key organ that can simultaneously target all three key organs involved in glucose balanceimeglimin has been shown to reduce blood sugar by increasing insulin secretion, increasing insulin sensitivity, and inhibiting the effects of sugar isogenesis (gluconeogenesis)This mechanism also has the potential to prevent endothelial dysfunction and diastoic dysfunction, and has a protective effect on microvascular and large vascular defects caused by diabetesIn addition, imeglimin has a potential protective effect on the survival and function of beta cellsOn Theof Poxel and Sumitomo Pharmaceuticals in April and June this year, Poxel and japanese partner SumitomoPharmaceutical(http://published positive top-line data on two key Phase III clinical studies OF TIMES-1 and TIMES-3 for the treatment of patients with type 2 diabetes in JapanBoth studies reached the main endpoint: TIMES-1, at the 24th week of treatment, imeglimin significantly reduced blood sugar levels (p0.0001) and fasting blood sugar levels (p0.0001) compared to placeboIn TIMES-3, at week 16 of the treatment, imeglimin-insulin significantly reduced blood sugar levels (p0.0001) compared to placebo-insulinPoxel and Sumitomo Pharmaceuticals established a strategic partnership in October 2017 to develop and commercialize imeglimin in Japan, China, Korea and nine other Southeast and East Asian countries for the treatment of type 2 diabetes